EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond glucose: wearable and implantable biosensors for continuous monitoring of metabolic, hormonal, and inflammatory biomarkers in personalized cardiometabolic care

Hong Cai, Yehui He, Chaoyue Wang, Yiqun Zhao, Chunhui Yang

Frontiers in Bioengineering and Biotechnology · 08.07.2026 · 14

DOI: 10.3389/fbioe.2026.1885022 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Bioengineering and Biotechnology, online erschienen am 08.07.2026. Verfasst von Hong Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 144 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Wearable and implantable biosensors are shifting biochemical assessment from episodic laboratory testing to continuous, context-rich physiological monitoring. Glucose remains the most successful translational model because continuous glucose monitoring has already established a credible pathway for analytical validation, clinical adoption, reimbursement, and regulatory approval. Yet cardiometabolic disease is not a single-analyte disorder. Insulin resistance, obesity, hypertension, heart failure, chronic kidney disease, stress-axis dysregulation, and chronic low-grade inflammation arise from interacting metabolic, endocrine, neural, and immune pathways. The next phase of the field therefore depends on whether biosensors can move beyond glucose while remaining biologically interpretable and clinically actionable. In this narrative review, we argue that personalized cardiometabolic care is the most attractive entry point for next-generation wearable and implantable biosensors because it combines high disease burden, dynamic physiology, rich biomarker biology, and an already established translational archetype. We integrate two complementary perspectives: a biomarker-centered framework that prioritizes glucose, lactate, ketones, uric acid, electrolytes, renal metabolites, cortisol, catecholamines, cytokines, acute-phase proteins, and selected cardiac markers; and a device-centered framework that examines sweat patches, microneedle-enabled interstitial fluid sensors, implantable systems, smart textiles, oral and ocular platforms, and hybrid closed-loop architectures. Particular emphasis is placed on biomarker-biofluid-device matching, the distinction between laboratory equivalence and continuous phenotyping, and the engineering barriers that determine real-world success, including partitioning across biofluids, skin-device coupling, biofouling, foreign-body response, calibration drift, reversibility of affinity-based sensing, power management, and multimodal data interpretation. We further discuss materials and interface strategies such as laser-induced graphene, conductive polymers, carbon nanomaterials, metal-organic frameworks, anti-fouling hydrogels, zwitterionic coatings, and drug-eluting surfaces; disease applications spanning diabetes, metabolic syndrome, heart failure, cardio-renal disease, and diabetic wound care; and the analytical, regulatory, and human-factor requirements for clinical adoption. The central message is that beyond-glucose biosensing will succeed only if it remains glucose-informed: glucose should serve as the translational backbone onto which additional metabolic, hormonal, inflammatory, and cardiovascular signals are layered according to biological kinetics, matrix suitability, and clinical decision need.

Schlagwörter

Stichwörter der Autor:innen

cardiometabolic careimplantable biosensorsinflammatory proteinsmicroneedlesmultimodal sensingwearable biosensors

Autor:innen und Institutionen

  • Department of Clinical Laboratory, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
  • Information Center, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.

Zitieren

APA

Cai, H., He, Y., Wang, C., Zhao, Y., & Yang, C. (2026). Beyond glucose: wearable and implantable biosensors for continuous monitoring of metabolic, hormonal, and inflammatory biomarkers in personalized cardiometabolic care. Frontiers in Bioengineering and Biotechnology, 14. https://doi.org/10.3389/fbioe.2026.1885022

Vancouver

Cai H, He Y, Wang C, Zhao Y, Yang C. Beyond glucose: wearable and implantable biosensors for continuous monitoring of metabolic, hormonal, and inflammatory biomarkers in personalized cardiometabolic care. Frontiers in Bioengineering and Biotechnology. 2026;14. doi:10.3389/fbioe.2026.1885022

BibTeX
@article{Cai2026,
  author = {Cai, Hong and He, Yehui and Wang, Chaoyue and Zhao, Yiqun and Yang, Chunhui},
  title = {Beyond glucose: wearable and implantable biosensors for continuous monitoring of metabolic, hormonal, and inflammatory biomarkers in personalized cardiometabolic care},
  journal = {Frontiers in Bioengineering and Biotechnology},
  year = {2026},
  volume = {14},
  doi = {10.3389/fbioe.2026.1885022}
}
Kostenlos starten →